Rainbow Coral Corp (RBCC) 0.7299 $RBCC
RBCC: Federal Initiative Could Further Boost Personalized Medicine in U.S.
Business Wire - Wed Sep 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) is weighing options and considering future moves now that the Obama Administration has begun soliciting the medical community and the public for ideas on personalizing medical treatments to meet individual patient needs. The search for suggestions is the first step of the president's Precision Medicine Initiative (PMI), proposed last January - a wide-ranging $215 million federal program that could spell great opportunity for companies engaged in developing and distributing personalized medicine solutions, such as RBCC.
RBCC: New Jersey Initiates New Law Boosting Medication Assisted Treatment
Business Wire - Thu Sep 03, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) expects legislation in New Jersey giving additional credence and importance to Medication Assisted Treatment (MAT) programs to have a positive effect on patients and on distribution of Naltrexone, a drug MATs use to fight opioid addiction.
RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School
Business Wire - Mon Aug 24, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences (n3D) has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston (UTHealth) Department of Obstetrics, Gynecology, and Reproductive Sciences. The agreement covers studies on personalized pre-term labor management and treatments.
RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse
Business Wire - Wed Aug 19, 4:00AM CDT
Rainbow Coral Corp. (RBCC) has taken note of the Obama Administration's recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment (MAT) programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.
Naltrexone for Opioid Addiction Spotlighted in Vermont Treatment Grant
Business Wire - Thu Aug 13, 4:00AM CDT
Rainbow Coral Corp. (RBCC) hailed Vermont's recent winning of a $3 million grant to aid opioid addiction treatment in the Green Mountain State, and pledged to provide support for similar Medication Assisted Treatment (MAT) programs throughout the country utilizing Naltrexone.
RBCC Partner n3D To Start Global Distribution of 3D Bioprinting Technology
Business Wire - Tue Aug 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Nano3D Biosciences (n3D) has signed a major worldwide distribution agreement with Reprocell for its revolutionary three-dimensional bioprinting product lines. Under the pact, Reprocell will market and sell n3D's BioAssembler and Magnetic 3D Bioprinting products to academic and governmental-institute life science researchers as well as to the pharmaceutical and biotech industries.
RBCC: U.S. Alcohol Abuse Costs Go Beyond Dollars, Shows Need for Concrete Answers
Business Wire - Tue Jul 28, 4:00AM CDT
Americans are paying a high price when it comes to alcohol abuse in terms of health costs, lost productivity and law enforcement activities according to study after study. Rainbow Coral Corp. (RBCC) has been actively looking for solutions to this affliction, seeking out partners to distribute Naltrexone, a drug that impedes the cravings to drink.
RBCC: North American Substance Abuse Stats Show Growing Need for Solution
Business Wire - Thu Jul 23, 4:00AM CDT
Substance abuse numbers from the United States and Canada demonstrate Naltrexone has strong growth potential, strengthening Rainbow Coral Corp.'s (RBCC) plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.
RBCC Ready to Sign LOI with Canadian Medical Group
Business Wire - Tue Jul 21, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is discussing a letter of intent with a Canadian medical services group that treats alcohol addiction utilizing Naltrexone.
RBCC: Naltrexone's Growing List of Applications and Uses Expands Its Market Potential
Business Wire - Thu Jul 16, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it. As Naltrexone's acceptance and usage spreads, RBCC expects to enjoy greater revenues from the drug.
RBCC Nears Major Agreement to Distribute Naltrexone in Canada
Business Wire - Thu Jul 09, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is drawing closer to a milestone agreement with a partner company to distribute Naltrexone - an important prescription drug used in treatment of alcohol and opiate addiction - in Canada. When reached and implemented, the agreement will open a crucial new revenue stream for RBCC as the FDA-approved drug's previous success has resulted in increased demand for effective new Naltrexone treatments from a wide spectrum of patients.
RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
Business Wire - Tue Jun 02, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), VRX: 225.64 (-3.15)
RBCC Aggressively Pursuing Personalized Medicine Opportunities in Canada
Business Wire - Tue May 05, 4:00AM CDT
Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient's own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig's disease) and Parkinson's.
RBCC Targets Regenerative Medicine Leader to Build Out Partner Portfolio
Business Wire - Mon Apr 27, 4:00AM CDT
Following a series of productive meetings last week, biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) targeted an emerging leader in the field of regenerative medicine for addition to its growing partner portfolio.
RBCC Weighs Opportunities Following Successful Events Schedule
Business Wire - Mon Mar 23, 4:00AM CDT
Following several successful conferences, events, and cross-country meetings, Rainbow Coral Corp. (OTCBB: RBCC) is sizing up potential investment and joint venture partners to expand its portfolio.
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
Business Wire - Thu Feb 05, 4:00AM CST
Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 13, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company's joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
RBCC: Federal Initiative Could Further Boost Personalized Medicine in U.S.
Business Wire - Wed Sep 09, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) is weighing options and considering future moves now that the Obama Administration has begun soliciting the medical community and the public for ideas on personalizing medical treatments to meet individual patient needs. The search for suggestions is the first step of the president's Precision Medicine Initiative (PMI), proposed last January - a wide-ranging $215 million federal program that could spell great opportunity for companies engaged in developing and distributing personalized medicine solutions, such as RBCC.
RBCC: New Jersey Initiates New Law Boosting Medication Assisted Treatment
Business Wire - Thu Sep 03, 4:00AM CDT
Rainbow Coral Corp. (OTCBB:RBCC) expects legislation in New Jersey giving additional credence and importance to Medication Assisted Treatment (MAT) programs to have a positive effect on patients and on distribution of Naltrexone, a drug MATs use to fight opioid addiction.
RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School
Business Wire - Mon Aug 24, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences (n3D) has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston (UTHealth) Department of Obstetrics, Gynecology, and Reproductive Sciences. The agreement covers studies on personalized pre-term labor management and treatments.
RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse
Business Wire - Wed Aug 19, 4:00AM CDT
Rainbow Coral Corp. (RBCC) has taken note of the Obama Administration's recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment (MAT) programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.
Naltrexone for Opioid Addiction Spotlighted in Vermont Treatment Grant
Business Wire - Thu Aug 13, 4:00AM CDT
Rainbow Coral Corp. (RBCC) hailed Vermont's recent winning of a $3 million grant to aid opioid addiction treatment in the Green Mountain State, and pledged to provide support for similar Medication Assisted Treatment (MAT) programs throughout the country utilizing Naltrexone.
RBCC Partner n3D To Start Global Distribution of 3D Bioprinting Technology
Business Wire - Tue Aug 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Nano3D Biosciences (n3D) has signed a major worldwide distribution agreement with Reprocell for its revolutionary three-dimensional bioprinting product lines. Under the pact, Reprocell will market and sell n3D's BioAssembler and Magnetic 3D Bioprinting products to academic and governmental-institute life science researchers as well as to the pharmaceutical and biotech industries.
RBCC: U.S. Alcohol Abuse Costs Go Beyond Dollars, Shows Need for Concrete Answers
Business Wire - Tue Jul 28, 4:00AM CDT
Americans are paying a high price when it comes to alcohol abuse in terms of health costs, lost productivity and law enforcement activities according to study after study. Rainbow Coral Corp. (RBCC) has been actively looking for solutions to this affliction, seeking out partners to distribute Naltrexone, a drug that impedes the cravings to drink.
RBCC: North American Substance Abuse Stats Show Growing Need for Solution
Business Wire - Thu Jul 23, 4:00AM CDT
Substance abuse numbers from the United States and Canada demonstrate Naltrexone has strong growth potential, strengthening Rainbow Coral Corp.'s (RBCC) plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.
RBCC Ready to Sign LOI with Canadian Medical Group
Business Wire - Tue Jul 21, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is discussing a letter of intent with a Canadian medical services group that treats alcohol addiction utilizing Naltrexone.
RBCC: Naltrexone's Growing List of Applications and Uses Expands Its Market Potential
Business Wire - Thu Jul 16, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) reports its flagship drug Naltrexone continues to gain widespread acceptance in the medical world as researchers discover more and more practical and beneficial uses for it. As Naltrexone's acceptance and usage spreads, RBCC expects to enjoy greater revenues from the drug.
RBCC Nears Major Agreement to Distribute Naltrexone in Canada
Business Wire - Thu Jul 09, 4:00AM CDT
Biotech company Rainbow Coral Corp. (RBCC) is drawing closer to a milestone agreement with a partner company to distribute Naltrexone - an important prescription drug used in treatment of alcohol and opiate addiction - in Canada. When reached and implemented, the agreement will open a crucial new revenue stream for RBCC as the FDA-approved drug's previous success has resulted in increased demand for effective new Naltrexone treatments from a wide spectrum of patients.
RBCC Explores New Pharmaceutical Compounding Opportunities in Booming Personalized Medicine Industry
Business Wire - Tue Jun 02, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB:RBCC) works to diversify its rapidly growing biotech business, the company is exploring new opportunities to provide innovative new products and services to the pharmaceutical compounding industry.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), VRX: 225.64 (-3.15)
RBCC Aggressively Pursuing Personalized Medicine Opportunities in Canada
Business Wire - Tue May 05, 4:00AM CDT
Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient's own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig's disease) and Parkinson's.
RBCC Targets Regenerative Medicine Leader to Build Out Partner Portfolio
Business Wire - Mon Apr 27, 4:00AM CDT
Following a series of productive meetings last week, biotech innovator Rainbow Coral Corp. (OTCBB: RBCC) targeted an emerging leader in the field of regenerative medicine for addition to its growing partner portfolio.
RBCC Weighs Opportunities Following Successful Events Schedule
Business Wire - Mon Mar 23, 4:00AM CDT
Following several successful conferences, events, and cross-country meetings, Rainbow Coral Corp. (OTCBB: RBCC) is sizing up potential investment and joint venture partners to expand its portfolio.
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
Business Wire - Thu Feb 05, 4:00AM CST
Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 13, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) executive leadership will preview the latest innovations and network with top biotechnology investors this week at Biotech Showcase 2015 in San Francisco, where the company's joint venture partner, Nano3D Biosciences (n3D) will exhibit the revolutionary Bio-Assembler device.
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 43.41 (+0.29), BIIB: 315.37 (+2.75), AMGN: 153.21 (+0.07)
